Docs report 235 Trasylol patient deaths

Here's some somber news: The FDA has tallied more than 200 reports of deaths linked to Trasylol, the suspended blood-clotting drug made by Bayer. Since 1993, when the drug was approved, doctors and other healthcare providers reported the deaths of 235 patients who received Trasylol during heart-bypass surgery.

There's no proof that Trasylol caused every one of these deaths. But you'll recall that Canadian regulators halted a clinical trial when early data seemed to show Trasylol might raise the risk of death by 50 percent. FDA then told Bayer to withdraw the drug while agency researchers pored over this new information.

This latest brouhaha follows a dust-up last year, when an FDA panel met to review data that linked Trasylol to a higher risk of death, kidney and heart failure, and stroke. The panel voted to keep the drug on the market, but then a whistleblower tipped off the FDA that Bayer had hidden an additional study about those risks. Bayer conducted an investigation and concluded that the info just fell through the cracks because of "human error."

Now Bayer has posted that study on its Trasylol website. It's not very encouraging. The researchers concluded that patients given Trasylol were more likely to die or experience kidney failure than were patients given aminocaproic acid. And the increased risk couldn't be attributed to the fact that more high-risk patients were given Trasylol.

- read the report in The New York Post
- see the Trasylol study

Related Articles:
Bayer braces for looming Trasylol review. Report
Investigator: Bayer did not hide Trasylol data. Report
Bayer kept Trasylol safety study hidden from FDA. Report

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.